[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533026":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":48,"collaborators":18,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":18,"maxAge":18,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":74,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","Oral folic acid 50 mcg daily starts at 14 days of age",[13],"Dietary Supplement: Folic acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","No additional folic acid supplementation",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIETARY_SUPPLEMENT","Folic acid","Infants allocated to the intervention group will receive folic acid (50 mcg flat dose\u002Fday) starting at 14 days of age.",[9],[26],{"name":27,"affiliation":5,"role":28},"Belal Alshaikh, MD, MSc","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","(403) 956 1588","belal.alshaikh@ahs.ca",[35],{"facility":36,"status":18,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":18},"Foothills Medical Centre","Calgary","Alberta","T2N2T9","Canada","CA",{"type":43,"coordinates":44},"Point",[45,46],-114.08529,51.05011,{"lat":46,"lon":45},{"type":49,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100533026","folic-acid-supplementation-to-reduce-anemia-in-extremely-preterm-infants-100533026",false,"NCT06220461","Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants","Folic Acid Supplementation to Reduce the Severity of Anemia and Blood Transfusions in Extremely Preterm Infants","FASCINATE","Inclusion Criteria:\n\n* Infants born at \\\u003C29 weeks of gestational age admitted to Foothill Medical Centre.\n* Postnatal age 14 days.\n* On minimum enteral feeding of 100 mL\u002Fkg\u002Fday\n\nExclusion Criteria:\n\n* Infants with major congenital or chromosomal anomalies\n* Infants with ongoing pulmonary or gastroenterology hemorrhage by 14 days of life.","ALL",{"count":60,"type":61},90,"ESTIMATED","INTERVENTIONAL",[64],"NA","Anemia of Prematurity (AOP) is very common in extremely preterm infants and often leads to blood transfusions. Folic acid, essential for growth and DNA synthesis, is deficient in premature infants. Despite the adoption of folic acid supplementation, evidence supporting its effectiveness in preventing AOP remains scarce. Recommendations for folic acid intake exceed what's naturally found in breast milk, particularly for extremely low birthweight infants. Practices regarding folic acid supplementation vary widely, prompting the need for research. The FACINATE trial aims to determine if additional folic acid supplementation improves hemoglobin levels and reduces late blood transfusions in extremely preterm infants, a question not addressed in current literature.",[67,68],"Extreme Prematurity","Anemia of Prematurity",[70,71,72,73],"extreme preterm","folic acid deficiency","anemia of prematurity","neonatal blood transfusion","NOT_YET_RECRUITING","2024-05-08",{"date":77,"type":78},"2024-05-09","ACTUAL",{"date":80,"type":61},"2024-06-01",{"date":82,"type":61},"2028-07-31",{"name":5,"class":6},1]